Tumor Necrosis Factor (TNF) Alpha Blockers

Rheumatoid arthritis drugs Remicade, Enbrel, Humira, and Cimzia have been linked to a possibly fatal fungal infection.  The FDA has issued an order requiring a black box warning label for the risk of histoplasmosis.  Histoplasmosis, a fungal infection with flu-like symptoms, can spread beyond the respiratory system and attack other internal organs.  240 cases have been reported, with a fatality rate of around 20%.

Remicade, Enbrel, Humira, and Cimzia are all drugs classified as tumor necrosis factor alpha blockers designed to treat rheumatoid arthritis and other serious diseases.  Remicade (infliximab) is manufactured by Centocor (Johnson & Johnson).  Enbrel (etanercept) is manufactured by Amgen and Wyeth.  Humira (adalimumab) is manufactured by Abbott Laboratories.  Cimzia (certolizumab pegol) is manufactured by UCB.

Larry H. Parker's team of nationally recognized pharmaceutical litigation lawyers have helped thousands of people successfully fight the big drug manufacturers.  We have successfully pursued numerous lawsuits involving pharmaceutical drugs, including Vioxx®, fen-phen, and Ortho Evra® and have represented our clients' interests against the manufacturers of Prempro®, Baycol®, and Fosamax®.  Our record of success speaks for itself.

To schedule a FREE, confidential, no obligation consultation, contact us via email using our case submission form or by phone at (800) 333-0000.  If we don't get you any money, we won't charge you a dime.  The Law Offices of Larry H. Parker has office locations in Long Beach, Los Angeles, Riverside, Bakersfield, and Fresno, California and Phoenix and Tucson, Arizona.

Remicade® is a registered trademark of Centocor, Inc.  Enbrel® is a registered trademark of Amgen and Wyeth Pharmaceuticals.  Humira® is a registered trademark of Abbott Laboratories.  Cimzia® is a registered trademark of UCB Pharma, S.A.